Score system to estimate the 12-month PFS and EFP*
Regimen | Points PFS | Points EFP | Total points PFS | PFS | Total points EFP | EFP |
Anti CTLA4-combo | 0 | 0 | ||||
Anti PD-(L)1 mono | 56 | 24 | ||||
Prior lines (n) | Points PFS | Points EFP | 237 | 0.1 | 134 | 0 |
0 | 0 | 0 | 225 | 0.15 | 127 | 0.05 |
1 | 12 | 8 | 213 | 0.2 | 120 | 0.1 |
2 | 25 | 17 | 201 | 0.25 | 114 | 0.15 |
3 | 37 | 25 | 190 | 0.3 | 107 | 0.2 |
4 | 50 | 34 | 178 | 0.35 | 100 | 0.25 |
5 | 62 | 42 | 166 | 0.4 | 94 | 0.3 |
6 | 75 | 50 | 155 | 0.45 | 87 | 0.35 |
7 | 87 | 59 | 143 | 0.5 | 81 | 0.4 |
Platelets (×1000) | Points PFS | Points EFP | 131 | 0.55 | 74 | 0.45 |
0 | 0 | 0 | 119 | 0.6 | 67 | 0.5 |
100 | 10 | 10 | 108 | 0.65 | 61 | 0.55 |
200 | 20 | 20 | 96 | 0.7 | 54 | 0.6 |
300 | 30 | 30 | 84 | 0.75 | 47 | 0.65 |
400 | 40 | 40 | 73 | 0.8 | 41 | 0.7 |
500 | 50 | 50 | 61 | 0.85 | 34 | 0.75 |
600 | 60 | 60 | 49 | 0.9 | 28 | 0.8 |
700 | 70 | 70 | 37 | 0.95 | 21 | 0.85 |
800 | 80 | 80 | 26 | 1 | 14 | 0.9 |
900 | 90 | 90 | ||||
1000 | 100 | 100 | ||||
ECOG PS | Points PFS | Points EFP | ||||
0 | 0 | 0 | ||||
>0 | 33 | 27 | ||||
NLR | Points PFS | Points EFP | ||||
≤3 | 0 | 0 | ||||
>3 | 25 | 12 |
*The PFS points are those shown in the figure 1 nomogram.
CTLA-4, cytotoxic T-lymphocyte antigen 4; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EFP, event-free probability; NLR, neutrophil-to-lymphocyte ratio; PD-(L)1, programmed death (ligand)1; PFS, progression-free survival.